Leprosy is a chronic disease caused by My cobacterium leprae, which has tropism to peripheral nerves, skin and mucosa where bacilli are fo und in large numbers in lepromatous leprosy (LL) patients. Infection with micro-organisms through skin and mucosa generally elicits specific antibody predominantly of the IgA class. However, the IgA antibody response in leprosy patients has so far escaped attention.
Since phenolic glycolipid-I (PGL-I) species-specific antigen to M. leprae was discovered, I several studies have attempted to evaluate the humoral response of the host. 2 , 3 However, despite the tropism of M. leprae to skin and mucosa we do not know if PGL-I elicits IgA class antibodies and what significance they might have for disease development. The lack of knowledge about the development of immune response in leprosy patients is due to the long incubation period between infection and clinical disease, so by the time the diagnosis is made the individual has already been ill for a long period of time. That makes it impossible to study the immunological response imme diately after primary infection with M. leprae.
The sooty mangabey monkey (Cercocebus torquatus atys) has been reported to be a good model to study the immune response to leprosy, because it has a course of infection similar to humans. 3 The aim of this paper is to evaluate the immune response of IgA class antibodies to species-specific PGL-I antigen by ELISA in the sera of 8 mangabey monkeys inoculated with M. leprae suspension and to correlate it with anti-PGL-I IgG and IgM titers, PGL-I in serum, and clinical course of the disease.
Material and methods
The animals' conditions, methods of My cobacterium leprae inoculation, the clinical evaluation before and after inoculation, and IgG and IgM results have been described previously. 3 Briefly, four pairs of mangabey monkeys were inoculated with M. leprae suspension by combined intravenous and intradermal routes. Monkeys number D 171 and DIn received 4·8 x 10 10 acid-fast bacilli (AFB), Dl73 and Dl74 were inoculated with 4·8 x 10 9 AFB, D175 and Dl76 received 4·8 x 10 8 AFB, Dl77 and D178 received 4·8 x 10 7 AFB. Two hundred and four serum samples were obtained over a 95-month period. There were two samples from each monkey 3 months before M. leprae inoculation and an average of 25 samples from each animal over 90 months after inoculation.
ENZ YME-LINKED IM M UNOSORBENT ASSAY (ELISA) FOR IGA
The disaccharide moiety of PGL-I coupled to bovine serum albumin (D-BSA, provided by WHO) was used to measure IgA antibody levels. The detection of antibody IgA anti-PGL-I by ELISA serological test was performed as briefly described. 4 Flat bottom, polystyrene microplates (Nunc) were coated with 50 pJ/well of D-BSA and BSA, respectively, diluted 100 ng/ml in 0·05 M sodium carbonate buffer pH 9·6 for 2 h at 37°C.
The plate was blocked with 100 pJ/well of 1 % bovine albumin in phosphate-buffered saline containing 0·1 % v/v Tween 20 (BSA-PBST). After incubation for 1 h at 37°C, 50 pJ of test monkey serum diluted 1 : 10 in 1 % BSA-PBST was added and incubated as before. Then 50 J.1J/well of mouse monoclonal peroxidase labelled anti-human IgA antibody (Nordic) was added, diluted 1: 300 in BSA-PBST. After incubation and washing 50 J.1J/well of substrate solution containing 18 mM 2-2 ' azino (3-ethyl-benzthia zoline-6-sulphonic acid) (ABTS; Boehringer) and 2·9 mM H 2 0 2 in citrate-phosphate buffer pH 5·0 were added. After incubation for 1 h at room temperature in the dark the reaction was stopped by the addition of 50 J. 1Jjwell of 0·32% (w/v) NaF. Extinction (L'.I.E) was read with a double wavelength micro ELISA autoreader MR 580 (Dynatech) at 405 nm (versus 490 nm) against a blank made up of substrate and stop solution. Known positive and negative control reference sera were included on each tray. Blank antigen wells were assayed in parallel to ensure that positive readings were, in fact, due to specific interactions between antibodies and the antigen. Each serum was tested twice and in duplicate. A serum was considered positive when the OD exceeded by two standard deviations (SD) the mean of results obtained before monkeys' inoculation with M. /eprae (cutoff = 0' 17).
ELISA DETERMINATION OF IGG AND IGM ANTI PGL-I
The assays were performed as previously reported, 3 , 5 but with some modifications, described in detail below, to ensure maximum accuracy and reproducibility. Natural PGL-I was used as antigen and was provided by Dr Brennan (Fort Collins, CO, USA).
Briefly, 96-well plates were coated with antigen (Ag), washed and blocked with BSA, washed again and reacted with a previously determined optimal dilution of monkey serum. After incubation and washing, the plates were coated with peroxidase-labelled anti-human IgG or IgM Fc fragment gamma or p,-chain-specific antibody diluted according to prior titrations, incubated, washed, reacted with o-phenylenediamine plus H 2 0 2 , acidified and OD's were determined at 490 nm on an ELISA reader. 3 Final OD's represent the difference in absorbance between wells containing Ag minus wells lacking Ag. Each reagent in the ELISA was carefully titrated in a checkboard manner to determine dilutions that would give final OD values between 0· 1 and 0·5 OD whenever possible to utilize the OD range most sensitive to small changes in OD. This way longitudinal changes also would be accurately reflected. All sera were assayed together at one time in given experiments to permit accurate relative comparisons. The same batch of peroxidase antibody was used throughout. All experiments were done at least twice. OD values obtained with these precautions were reproducible in a given sample from one assay to another to within ±0·05. The mean + 2 SD, taken as the cutoff points, respectively, were 0·043 and 0·073 for IgG and IgM.
DETECTION OF PGL-I ANTIGEN IN SERA
The PGL-I antigen assay was performed as described previously. 6 Briefly, for serum lipid extraction, 100 p,l of serum was added to filter paper discs (0'5 " in diameter) and dried completely. Lipids were then extracted using 2-3 ml of chloroform : methanol (2 : 1) solution and dried under N 2 . Serum lipids were dissolved in chloroform and applied to fluorosil packed in a Pasteur pipette, 60-100 mesch (Sigma Chemical Co. St Louis, MO., USA) and eluted with chloroform, fo llowed by 5% methanol in chloro fo rm. The lipid fraction eluted with 5% methanol was saved and dried under N 2 and examined for the presence of PGL-I by a dot-ELISA method as previously reported. 6 The lipid fraction was dissolved in 100 J.Ll of hexane and a 5-J.Ll portion was applied to a tuffryn (polysulphone) membrane (HT-200) (Gelman Sciences Inc., Ann Arbor, MI, USA), fo llowed by anti-PGL-I antibody. A high titer of rabbit anti-PGL-I antibody (a gift from Dr P. J. Brennan) was used for the primary antibody and peroxidase conjugated goat anti-rabbit IgG (Cooper Biomedical Inc., Malvern, PA, USA) was used as the secondary antibody. For colour development, 4-chloro-1-naphthol (Biorad Laboratories, Richmond, CA, USA) was used and the results were read visually.
Results
We demonstrated that the majority of monkeys developed IgA antibody against PGL-I. In six animals (6/8, 75%) increasing IgA levels were detected after M. leprae inoculation (D 171, D173, D174, D176, Dl77, D178).
Three monkeys (D 1 74, D176 and Dl77-3/6, 50%) showed high anti-PGL-I IgA levels (bE > 0·5) ( Monkey D 176 showed a much more rapid clinical evolution of disease than any of the other animals, LL clinical symptoms were noted at 4 months with progressive evolution, thereafter requiring treatment at 27 months with rifampicin, and the complete remission of the disease was observed at 35 months. 3 No neurological signs have been noted. A low IgA peak appeared at 10 months pi and a second higher peak was seen at 24 months pi. On the other hand, D 177 showed a slow development of clinical leprosy (LLs) by 26 months pi. The treatment with rifampicin was started at 42 months pi. Nerve enlargement was detected at 47 months pi and persisted after chemotherapy. 1 5 IgA appeared shortly after IgG and IgM and the highest peak of IgA appeared shortly (at 47 months pi) after treatment and corresponded to the beginning of the neurologic damage.
In these three monkeys early (within 3 months pi) anti-PGL-I IgG antibody titers were observed: moderate in D174, high in D176 and low in Dl77. IgM level in the same period was lower. The initial IgG and IgM were fo llowed by a second or third peak that corresponded to periods of progression of the disease and higher serum concentration of PGL-I antigen in serum (Figure l(a) and (b) ). PGL-I in serum, as expected, decreased quickly after treatment. Anti-PGL-I IgG and IgM decreased slowly after treatment, but anti-PGL-I IgA decreased slower in D174 and Dl77 (Figure l(a) ).
In the other three monkeys (3/6, 50%) a low IgA response was found (D 171, D 173 and D178) (Figure 2 titer was found late (at 60 months pi) after the appearance of IgG and IgM as well as after highest serum peak ofPGL-I, and treatment. A second low IgA antibody peak, but higher than the first one, was detected at 90 months pi. Early (within 3 months pi), moderate IgG antibodies and very low IgM antibodies titers were fo und. IgG antibodies persisted and IgM antibodies rose corresponding with PGL-I concentration in serum and to the periods of clinical progression of disease. IgG and IgM antibodies and PGL-I antigen in serum decreased rapidly after chemotherapy, while IgA was still being elicited. The animal D 173 developed indeterminate leprosy (I) at 5 months pi but by 14 months the disease regressed. 3 Neurological signs appeared at 85 months pi, fo llowed by progression to LL. Chemotherapy was given at 105 months pi Y Low IgA antibody titers appeared late after IgG and IgM and shortly (at 86 months pi) after aggravation of disease. Initial moderate IgG and very low IgM antibody levels were fo llowed by a second high peak and low, respectively. IgG decreased slowly after 60 months pi. PGL-I antigen was not detected in serum.
D 178 developed I leprosy by the 35th month pi. The indeterminate lesion of leprosy regressed spontaneously, however the nerve enlargement persisted. 3 A low early IgA peak appeared at the same time as IgG in the absence of disease, a second IgG peak • PG.·1 Ag .
-f"'I""T"'I'" "T"'P"T" "I'" "T" "O" ""T" "I'" "T" ""'"T" "Ir"T" "r-r"1 M 0 N TH (Figure 3 ). Monkey D In developed LL at 9 months pi but the disease spontaneously regressed to 1. 3 Relapse and regress of the disease happened several times during the fo llow-up (Figure 3(b) ). It developed neurological signs at 39 months pi which persisted; chemotherapy was given at 65 months pi. IgG and IgM seemed to correspond to the appearance of PGL-I in serum and the development of the disease. PGL-I antigen disappeared much more rapidly in DIn than in any of the other monkeys. Mangabey D175 did not develop clinical symptoms of leprosy, mounted an early predominantly low IgG response and PGL-I was not detected in serum ( Figure  3(b ) ).
Discussion
We report the detection of IgA to species-specific PGL-I antigen to M. leprae in serum of mangabey monkeys inoculated with M. leprae suspension over the entire course of the infection (over 90 months).
In this study the majority of animals presented increased levels of IgA after M. leprae inoculation (75%). An interesting finding was the presence of high levels of IgA after the appearance of clinical symptoms while the rise of IgG and IgM levels preceded the symptoms (D I71, D173, D174, D176 and DIn). It is already known that systemic immunization elicits preferentially IgM and IgG antibodies but a prolongated exposure to the antigens may induce high levels of serum IgA. 7 It is commonly believed that human LL patients produce predominantly IgM anti PGL-I, but our data show that in some monkeys anti-PGL-I IgG class is also elicited in significant quantities (4/7, 57%-DI71, DIn, D173, DI78). One reason may be a difference between humans and monkeys, it may also be due to the inoculation routes or to the fact that our study looked at earlier time periods post-infection compared to most human leprosy studies.
It is not known whether IgG anti-PGL-I is elicited early in the disease, but IgM has been reported to be present before s and after disease symptoms. Our data show that IgG and IgM anti-PGL-I can be produced in significant levels early after the inoculation of monkeys with M. leprae. Gormus et al. It is established that a humoral response is dependent on the cooperation of B and T cells. On the other hand, the occurrence of lepromatous leprosy is due to a deficient cellular response to M. leprae, an obligate intracellular parasite. A high IgA response in animals with lepromatous leprosy, especially in those under treatment, then, seems to be a controversial finding. The existence of IgA titers may be explained by recent studies where it has been reported that the cytokine TGF-,8 (transforming growth factor beta) enhances the IgA production by LPS stimulated murine B cells even in the absence of T cells.
I I Bullock l2 links the high serum IgA concentration in LL patients under therapy to the persistence of killed M. leprae in the tissues but we believe that other mechanisms may also be activated. The association of TGF-,8 with immunosuppression was previously shown and increased production of this cytokine was reported in patients with the acquired immune deficiency syndrome (AIDS Another result of particular interest is that anti-PGL-I IgA antibodies were found shortly after or coincident with neurologic damage (D I71, D173, D174, Din and DI78). Animals D174 and DIn produced IgA in excess of 1·0 OD. These monkeys seem to be more susceptible than the other animals. In D174 and Din, in which the clinical nerve symptoms persisted even after successful chemotherapy, the IgA antibodies remained at a high level for long periods of time (Figure 1 ). Mangabey monkeys D 171, D 173 and D 178 seemed less susceptible to leprosy infection and produced low anti-PGL-I IgA antibody levels. Although D171 developed extensive disease in the beginning, it responded very well to chemotherapy and, as animal D173, developed neurologic signs later after regression of the disease. Mangabey D 178 showed symptoms of leprosy nerve enlargement with indeterminate lesions of leprosy in the skin regressing spontaneously. Antibody responses to human nerve antigens have been reported in these monkeys, but it is not clear if these antibodies or anti-PGL-I IgA play some role in the pathogenesis of the disease.
IS If IgA antibodies were elevated only in the context of a wider humoral response against PGL-I of either IgG and IgM (as in DI76), doubts may be cast on the possible significance of this immunoglobulin, but in some monkeys high IgA antibody levels were detected even when IgG or/and IgM were low or decreasing (D l71, D173, D174 and DIn). On the other hand, anti-PGL-I IgG and IgM have been elicited early pi and both immunoglobulins or one of them arose fo llowing the progression of the disease, so maybe the damage to peripheral nerves was originally caused by these two antibodies, and in this case the late increase of IgA may be involved in the amplification of the neurological damage. Or alternatively, anti PGL-I IgA may play a protective role from attack by humoral or cellular factors.
Several fluctuations in the antibody response and in the clinical evolution of disease between the monkeys studied were noted, which is perhaps influenced by intrinsic factors of the host, such as his cell-mediated immunity, environmental factors and the strain of M. ieprae.
The interpretation of our data may not be simple. Leprosy seems to elicit a particular immune response. During the course of HIV induced-immunosuppression, tuberculosis, among other opportunistic infections, tends to appear. However, in a recent report no evidence of an association between the incidence of leprosy and HIV infection was found. 14 The authors suggest that leprosy may have a particular immune response mechanism. In our study the immunological events have been orchestrated since the monkeys were experimentally inoculated with M. ieprae. Many cells and cytokines have played a role in the activation and suppression of the immune response and during this process the disease developed. The availability of an experimental model would be helpful in designing a longitudinal study to evaluate not only if IgA antibodies play a role in leprosy but also to study the interactions between lymphocyte subsets and cytokines produced and the humoral response in leprosy.
